Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Privia Health Group, Inc. (Nasdaq: PRVA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Privia Health is a Delaware-incorporated, technology-driven physician enablement company based in Arlington, Virginia, and its filings offer detailed information about its financial condition, operations, governance, and material events.
Among the most frequently referenced documents are current reports on Form 8-K, which Privia Health uses to announce quarterly financial results, guidance updates, and other significant developments. For example, the company has filed 8-Ks to furnish press releases covering its first, second, and third quarter results, including metrics such as total revenue, net income, Adjusted EBITDA, Implemented Providers, Value-Based Care Attributed Lives, Practice Collections, Care Margin, and Platform Contribution. It has also filed 8-Ks to describe material events like the definitive agreement to acquire an Accountable Care Organization business from Evolent Health, Inc., and changes in its Board of Directors.
Investors analyzing PRVA can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR) to review segment information, risk factors, non-GAAP reconciliations, and detailed discussions of the company’s value-based care model and physician enablement platform. These filings also elaborate on regulatory risks, relationships with medical groups and providers, and dependencies on key technology vendors.
On Stock Titan, Privia Health filings are complemented by AI-powered summaries that explain the key points of lengthy documents such as 10-Ks and 10-Qs, and highlight notable items in 8-Ks. Users can quickly see what changed from prior periods, how management describes performance in value-based care programs like the Medicare Shared Savings Program, and where guidance or risk disclosures have been updated. The platform also surfaces relevant insider and governance-related filings, helping readers track board appointments, compensation plans, and other corporate actions disclosed to the SEC.
David Mountcastle reported proposed sales of Common stock under a Form 144 filing.
The filing lists four option-originated Common share lots associated with option grant dates
The filing also discloses actual Common stock sales by David Mountcastle during the past three months: 23,887 shares sold on
Privia Health Group, Inc. files its annual report describing a technology-driven physician-enablement business focused on value-based care across 24 states and the District of Columbia. The company supports 5,380 Privia Providers at over 1,300 locations, caring for more than 5.8 million patients.
Privia highlights its ACO performance, including $233.1 million of 2024 Medicare Shared Savings Program shared savings, a 32% increase over 2023, and per-member costs and utilization that were meaningfully below fee-for-service Medicare. The filing also outlines extensive healthcare, data privacy, and regulatory risks that could affect future operations.
PRVA filing reports a proposed sale of company common shares under a Form 144. The notice lists option-originated shares dated
Privia Health Group reported strong fourth quarter and full-year 2025 results, with every major operating and financial metric at or above the high end of its guidance ranges. Full-year revenue reached
Non-GAAP adjusted net income grew
Cash generation was robust, with net cash provided by operating activities of
A director of Privia Health Group, Inc. reported an option exercise and related stock sale on 12/12/2025. The director exercised stock options covering 13,647 shares of common stock at an exercise price of $2 per share and on the same day sold 13,647 shares at a weighted average price of about $25.01 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, the director directly owned 68,188 shares of Privia Health common stock and held additional indirect ownership of 12,487 shares through Emerald Family, LLC and 11,998 shares through a trust. The director also held 3,716,652 fully vested stock options with an exercise price of $2 per share that are exercisable until 08/27/2033.
Privia Health Group’s executive vice president and chief financial officer reported an insider transaction involving stock option exercises and a related share sale on 12/12/2025. She exercised stock options at an exercise price of $2 per share, acquiring 23,887 shares of common stock, and then sold 23,887 shares of common stock at a weighted average price of $25.03 per share under a previously adopted Rule 10b5-1 trading plan.
After these transactions, she beneficially owned 172,909 shares of common stock directly and 8,695 shares indirectly through her spouse. She also continued to hold fully vested and exercisable stock options with remaining positions including 17,820, 12,452, 5,501 and 2,866 options, each relating to common stock at a $2 exercise price, with expiration dates ranging from 08/27/2028 to 09/07/2030.
Privia Health Group (PRVA) reported Q3 results highlighting strong growth and solid liquidity. Revenue reached $580.4 million, up from $437.9 million, with operating income of $14.4 million versus $5.8 million. Net income attributable to Privia was $6.9 million ($0.05 diluted EPS), compared with $3.5 million a year ago. Value-based care momentum continued as shared savings benefited from a $23.8 million change in estimate tied to the 2024 MSSP performance.
Cash and cash equivalents were $441.4 million, and no amounts were drawn on the $125 million revolving credit facility. Accounts receivable rose to $499.0 million, reflecting higher volumes and VBC accruals, while provider liability increased to $495.7 million. The company closed the PMG-AZ acquisition, adding $64.4 million of payer/physician network intangibles and $30.6 million of goodwill; PMG-AZ contributed $37.0 million of revenue post-close.
After quarter-end, Privia received $156.9 million from CMS for 2024 MSSP shared savings, of which $88.4 million will be disbursed to providers, and signed a definitive agreement to acquire an ACO business from Evolent Health for $100.0 million in cash plus up to $13.0 million, subject to customary conditions.
Privia Health Group, Inc. furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release on November 6, 2025, attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is stated as “furnished” and not “filed” under the Exchange Act. Privia Health’s common stock trades on the Nasdaq Global Select Market under the symbol PRVA.
Privia Health Group, Inc. (PRVA) reported the passing of Board member Patricia Maryland on October 24, 2025. She served on the Board for five years and was Chair of the Compliance Committee. The company expressed gratitude for her service and contributions.
The report is filed under Item 8.01 (Other Events) and was signed by Chief Executive Officer Parth Mehrotra. No additional board or committee actions are described in this disclosure.
Privia Health Group, Inc. (PRVA) filed a Current Report describing material risks and uncertainties affecting its business. The filing highlights regulatory and compliance exposure in a heavily regulated healthcare environment, the complexity of relationships with medical groups and Privia providers, and execution risks for its growth strategy and proprietary cloud-based technology rollout. It notes reliance on key vendors such as athenahealth, Inc., potential reimbursement rate pressure from government and private payers, cybersecurity and privacy risks related to protected health information, and workforce availability and cost pressures. The report references risk disclosures through year ended December 31, 2024 and states information is current as of the report date.